Ani Pharmaceuticals Stock News

ANI (ANIP) delivered earnings and revenue surprises of -250% and 1.56%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Alimera Sciences (ALIM) delivered earnings and revenue surprises of -26.87% and 8.48%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Intellia Therapeutics, Inc. (NTLA) delivered earnings and revenue surprises of -76.58% and 8.80%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the s

BAUDETTE, Minn.--(BUSINESS WIRE)--ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced that the Company will release its first quarter 2022 financial results on Tu

Pharmaceutical stocks are great wealth builders. But you need to discover how to use them and what to avoid.

U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining 350 points on Tuesday. The Dow traded up 1.07% to 33,297.32 while the NASDAQ rose 1.81% to 12,809.09. The S&P also rose, gaining, 1.24% to 4,224.97. Also check this: Executives Sell More Than $25M Of 4 Stocks Leading and Lagging Sectors Consumer discretionary shares climbed by 2.7% on Tuesday. Meanwhile, top gainers in the sector included New Oriental Education & Technology Group Inc. (NYSE: EDU ), up 20% and Shift Technologies, Inc. (NASDAQ: SFT ) up 15%. In trading on Tuesday, energy shares fell by 3.3%. Top Headline US producer prices rose 0.8% from a month ago in February, versus a revised 1.2% increase in the previous month and slightly below analysts’ estimates of 0.9%. Equities Trading UP Incannex Healthcare Limited (NASDAQ: IXHL ) shares shot up 136% to $54.00 after jumping 54% on Monday. Incannex Healthcare recently completed a preliminary analysis of data from its Phase 2 trial of a cannabinoid combination product, IHL-42X, for obstructive sleep apnoea (OSA).

https://www.investing.com/news/stock-market-news/ani-pharmaceuticals-down-25-after-earnings-miss-2785166

The shares of ANI Pharmaceuticals <> have approached the lowest level since August after the maker of branded and generic medicines posted a lower than expected guidance for 2022

ANI Pharmaceuticals, Inc. (ANIP) CEO Nikhil Lalwani on Q4 2021 Results - Earnings Call Transcript

ANI Pharmaceuticals Inc''s (NASDAQ: ANIP ) Q4 revenues were $60.9 million , +6.4% Y/Y, beating the consensus of $56.30 million. Net revenues for generic pharmaceutical products were $41.6 million, +8% primarily due to the Novitium acquisition and Q3 launch of Nebivolol, tempered by sales declines for Tolterodine and Vancomycin and lower … Full story available on Benzinga.com

ANI (ANIP) delivered earnings and revenue surprises of -34.15% and 4.60%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Anaptys Discontinues Phase 2 Study Of Imsidolimab In Acne Anaptys Bio, Inc. (NASDAQ: ANAB) said the Ph

ANI Pharmaceuticals press release (ANIP): Q4 GAAP EPS of $0.54 beats by $0.68.Revenue of $60.9M (+6.3% Y/Y) beats by $4.6M.Cash and cash equivalents were $100.3 million, net…

ANI (ANIP) delivered earnings and revenue surprises of -34.15% and 4.60%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?